← UroGen Pharma Ltd.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $17.5m |
$8.2m
-53.46%
|
$1.1m
-86.17%
|
$18k
-98.40%
|
$11.8m
+65450.00%
|
$48.0m
+307.17%
|
$64.4m
+33.96%
|
$82.7m
+28.52%
|
$90.4m
+9.29%
|
$109.8m
+21.45%
|
$188.7m
+71.91%
|
|
| Cost of Goods and Services Sold | $28k |
$600k
+2042.86%
|
$1.8m
+200.50%
|
$0
-100.00%
|
$1.0m |
$5.2m
+411.10%
|
$7.7m
+48.42%
|
$9.4m
+22.30%
|
$8.9m
-5.13%
|
$12.4m
+40.15%
|
$17.3m
+38.81%
|
|
| Gross Profit | $17.5m |
$7.6m
-56.82%
|
($675k)
-108.93%
|
$18k
+102.67%
|
$10.8m
+59844.44%
|
$42.9m
+297.45%
|
$56.7m
+32.22%
|
$73.4m
+29.36%
|
$81.5m
+11.13%
|
$97.3m
+19.41%
|
$171.5m
+76.14%
|
|
| Research and Development Expense | — | — | — | $49.3m | $47.3m | $47.6m | $52.9m | $45.6m | $57.1m | $67.1m | $61.3m | |
| Selling, General and Administrative Expense | — | — | — | — | $90.2m | $87.5m | $82.8m | $93.3m | $121.2m | $155.1m | $176.9m | |
| Operating Lease, Expense | — | — | — | $1.2m | — | — | — | — | — | — | — | |
| Operating Expenses | — | — | $76.5m | $109.5m | — | — | — | — | — | — | $255.4m | |
| Operating Income (Loss) | $798k |
($19.9m)
-2600.00%
|
($77.2m)
-286.87%
|
($109.5m)
-41.85%
|
($126.7m)
-15.77%
|
($92.3m)
+27.18%
|
($79.0m)
+14.36%
|
($65.5m)
+17.09%
|
($96.8m)
-47.68%
|
($124.9m)
-29.01%
|
($66.7m)
+46.62%
|
|
| Foreign Currency Transaction Gain (Loss), before Tax | — | $3k | — | — | — | — | — | — | — | — | — | |
| Other Nonoperating Income (Expense) | — | — | — | ($284k) | — | — | — | — | — | — | — | |
| Interest and Other Income | — | — | — | — | — | — | $1.0m | $3.5m | $8.7m | $5.3m | — | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | ($1.9m) | ($20.0m) | ($75.5m) | ($105.1m) | ($125.1m) | ($109.4m) | ($108.0m) | ($98.3m) | ($124.0m) | ($153.4m) | ($98.1m) | |
| Income Tax Expense (Benefit) | — | $19k | $125k | — | $3.4m | $1.4m | $1.8m | $3.9m | $2.8m | $78k | ($472k) | |
| Net Income (Loss) Attributable to Parent | ($1.9m) |
($20.0m)
-930.40%
|
($75.7m)
-278.28%
|
($105.1m)
-38.98%
|
($128.5m)
-22.20%
|
($110.8m)
+13.75%
|
($109.8m)
+0.94%
|
($102.2m)
+6.87%
|
($126.9m)
-24.09%
|
($153.5m)
-20.98%
|
($97.6m)
+36.39%
|
|
| Net Income (Loss) Available to Common Stockholders, Basic | ($4.4m) |
($20.8m)
-372.44%
|
($75.7m)
-263.30%
|
($105.1m)
-38.98%
|
($128.5m)
-22.20%
|
— | — | — | — | — | ($97.6m) | |
| Preferred Stock Dividends, Income Statement Impact | $2.5m | $825k | — | — | — | — | — | — | — | — | — | |
| Earnings Per Share, Basic | ($1.91) | ($2.14) | — | — | — | — | ($4.81) | ($3.55) | ($2.96) | ($3.19) | ($1.97) | |
| Weighted Average Number of Shares Outstanding, Basic | 2.3m | 9.7m | — | — | — | — | 22.8m | 28.8m | 42.9m | 48.1m | 49.5m |